Thu, October 20, 2011
Wed, October 19, 2011
Tue, October 18, 2011
Mon, October 17, 2011
Sun, October 16, 2011
Sat, October 15, 2011
Fri, October 14, 2011
Thu, October 13, 2011
Wed, October 12, 2011
[ Wed, Oct 12th 2011 ] - Market Wire
Financial Statement 10/11
Tue, October 11, 2011
[ Tue, Oct 11th 2011 ] - Market Wire
Aetna??Michael Elliott???????
Mon, October 10, 2011
Sun, October 9, 2011
Sat, October 8, 2011
Fri, October 7, 2011
Thu, October 6, 2011
Wed, October 5, 2011
Tue, October 4, 2011
Mon, October 3, 2011
[ Mon, Oct 03rd 2011 ] - Market Wire
Medwell Capital to Adopt IFRS
Sun, October 2, 2011
Sat, October 1, 2011
Fri, September 30, 2011
Thu, September 29, 2011
Wed, September 28, 2011

Dynavax to Host Analyst &;; Investor Day Webcast October 27, 2011


//health-fitness.news-articles.net/content/2011/ .. -59-59-investor-day-webcast-october-27-2011.html
Published in Health and Fitness on Wednesday, October 12th 2011 at 12:55 GMT by Market Wire   Print publication without navigation


October 12, 2011 15:46 ET

Dynavax to Host Analyst & Investor Day Webcast October 27, 2011

BERKELEY, CA--(Marketwire - Oct 12, 2011) - Dynavax Technologies Corporation (NASDAQ: [ DVAX ]) announced today that it will webcast its 2011 Analyst & Investor Day on Thursday, October 27, 2011, from 8:00 - 11:00 a.m. Eastern Time.

Presentations and discussions by outside experts and the management team will focus on how Dynavax plans to translate the superior clinical results provided by HEPLISAV™, its investigational hepatitis B vaccine, to a commercial success. Dynavax will discuss its action plan, market opportunity, the regulatory landscape, the potential upside of a diabetic vaccination recommendation, and its TLR9-based approach that leverages the mechanism of action of natural immunity.

To access the live webcast and the subsequent archived audio recording of the presentation, please log on to Dynavax's website at [ http://investors.dynavax.com/newsevents.cfm ].

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than current licensed vaccines. For more information visit [ www.dynavax.com ].



Publication Contributing Sources